Company Filing History:
1 out of 28 
1 out of 10 Years Active: 2004-2009
Title: Inventor Spotlight: Helen Jackson
Introduction
Helen Jackson is a prominent inventor based in North Hill, GB. She holds two patents that reflect her innovative contributions to the field of biotechnology, particularly in cancer research. Her work focuses on developing specific binding proteins, which hold potential for groundbreaking methods of diagnosis and treatment.
Latest Patents
Helen's latest patents include innovations related to specific binding proteins, including antibodies that target the necrotic center of tumors. These patents describe the unique third CDR residues of the antibodies NH576 and NHS76, offering insights into their applications in treatment and diagnosis. Her work promises to enhance therapeutic approaches for cancer patients by facilitating more precise targeting of tumor sites.
Career Highlights
Throughout her career, Helen has made significant strides in biopharmaceutical development. She has worked with notable organizations such as Cambridge Antibody Technology Limited and Peregrine Pharmaceuticals, Inc., where she contributed her expertise to advance biomedical technologies. Her efforts have been pivotal in creating novel therapies that address critical medical challenges.
Collaborations
In her professional journey, Helen has collaborated with esteemed colleagues like Andrew James Williams and Philip Ronald Tempest. Their collective efforts have strengthened research initiatives and fostered innovation within the field, underscoring the importance of teamwork in scientific discoveries.
Conclusion
Helen Jackson exemplifies the spirit of innovation, demonstrating how inventors can play a vital role in revolutionizing healthcare through their inventions. With her ongoing commitment to research and collaboration, she continues to pave the way for future advancements in biotechnology that may significantly improve patient outcomes.